Grants for Nonprofits - Science and Technology

The NIST Hollings Manufacturing Extension Partnership (MEP), authorized by 15 U.S.C. 278k, is seeking applications from eligible applicants to enter into a cooperative agreement to operate an MEP Center in the State of Florida. The MEP Center will provide manufacturing extension services to small and mid-sized manufacturers (SMMs) in the State of Florida. The MEP Center will become part of the MEP National Network, which consists of 51 MEP Centers located in every State and Puerto Rico, and over 1,440 trusted advisors and experts at approximately 460 MEP service locations.

The McKean County Community Foundation (MCCF) awards grants through its McKean County Community Development Fund, an unrestricted fund aimed at enhancing the economic and community well-being of McKean County. This initiative aligns directly with the MCCF's mission to support community development, ensuring that vital resources are channeled to areas that will foster significant growth and improvement within the region. The grants are designed to be a catalyst for positive change, focusing on broad community benefit rather than specific individual needs. The primary beneficiaries of this grant program are nonprofit agencies operating within McKean County that are dedicated to community development initiatives. The overarching impact goal is to strengthen the economic and social fabric of the county by funding projects that address critical community needs and foster sustainable growth. While specific target populations within the county are not explicitly detailed, the focus is on initiatives that benefit the community as a whole, thereby elevating the quality of life for all residents. The MCCF prioritizes innovative projects that demonstrate a clear plan for long-term sustainability. The grants are not intended to cover an agency's direct operating expenses but rather to enhance existing programs or support the development of new, impactful initiatives. This strategic focus ensures that funding is used to build capacity and create lasting solutions, rather than simply maintaining the status quo. The foundation's theory of change emphasizes investment in creative solutions that have the potential for enduring community benefit. Expected outcomes include the successful implementation of innovative community development projects that contribute to the economic vitality and overall well-being of McKean County. While specific measurable results are not detailed in the provided information, the emphasis on innovation and sustainability suggests that successful projects would demonstrate tangible improvements in community indicators relevant to economic and social development. Approximately $10,000 is available this year, with a maximum grant request of $2,000 per applicant, indicating a strategy to support multiple smaller, impactful projects across the county.

The Rock Charitable Fund, administered by the Northern New York Community Foundation, is currently accepting applications for grants ranging from $100,000 to $500,000. This grant program aligns with the foundation's mission to support the well-being and historical preservation within St. Lawrence County, New York. The fund emphasizes projects that address existing structures and elements, as well as providing technical assistance and planning support, indicating a strategic priority on sustainable development and preservation rather than new construction or significant alterations to historic properties. The primary beneficiaries of the Rock Charitable Fund include 501(c)(3) charitable organizations, churches, houses of worship, cemeteries, and government entities. The fund targets projects that contribute to the maintenance and preservation of these institutions and places of historical significance within St. Lawrence County. Additionally, the fund aims to benefit and/or assist Veterans of the United States Military residing in St. Lawrence County by addressing their medical and recreational needs through qualified organizations. The impact goals are centered on enhancing community resources, preserving local heritage, and improving the quality of life for Veterans. The program's priorities and focus areas are clearly defined. For historical and religious properties, there's a strong preference for exterior projects that are publicly visible and accessible, though interior improvements may be considered. Peripheral or incidental projects are not desired. For cemeteries, support covers the property as a whole or aesthetically significant portions, explicitly excluding individual burial plots or monuments without special justification. For Veterans, grants are awarded to qualified organizations serving them, not directly to individuals, and can support programs for medical and recreational needs. This structured approach highlights a theory of change that leverages established organizations to create broader community benefit and long-term impact. Expected outcomes include the successful preservation and maintenance of historically significant sites and religious institutions, ensuring their continued benefit to the public. For Veterans, the anticipated result is improved access to medical and recreational support, contributing to their overall well-being. Measurable results could include the number of structures preserved, the extent of public access improved, and the number of Veterans served by supported programs. The foundation's strategic priorities are evident in its commitment to tangible, community-focused projects that have a lasting positive effect on St. Lawrence County's heritage and its Veteran population.

This grant provides funding to eligible organizations that support community programs focused on health, basic needs, workforce development, and youth development for low-income families in Wayne and Holmes Counties, Ohio.

The 2025 Arts & History Re-Grant Program, administered by the Cape May County Government in New Jersey, offers funding to support arts and history-related projects and ongoing programs within Cape May County. The program's mission aligns with fostering community engagement and increasing exposure to arts and history. It aims to support a diverse range of initiatives, from single events to sustained programming, ultimately enriching the cultural landscape of the county. The program targets organizations and groups located within Cape May County that are involved in arts or history. This includes civic organizations, social organizations, community theater groups, dance companies, museums, galleries, orchestras, and singing groups. The impact goals are to support and sustain arts and history projects, programs, and general operations, thereby enhancing cultural offerings and community participation in these areas. There are three distinct categories of funding: Special Project, General Programming Support (GPS), and General Operating Support (GOS). Special Project funding is for single, specific arts or history-related events. GPS supports major, ongoing arts programs with multiple events or activities throughout the year. GOS is designed for organizations whose primary charter is arts or history-related, providing general operating support to groups that consistently increase exposure to art/history in the community. The program prioritizes projects and programs that take place within Cape May County and, for General Operating Support, requires the applying organization to be located within the county. Expected outcomes include a more vibrant cultural scene in Cape May County, increased opportunities for residents to engage with arts and history, and the sustained operation of local arts and history organizations. Measurable results would involve the number and diversity of projects funded, the reach and attendance of programs, and the organizational stability of grant recipients. The strategic priorities revolve around making arts and history accessible, supporting the infrastructure of cultural organizations, and ensuring fiscal responsibility, particularly for General Operating Support grants. The program's theory of change posits that by providing targeted financial support, local cultural initiatives will thrive, leading to a more enriched and engaged community.

Maturing research ideas into clinical practice and patient benefit is at the heart of all CDMRP research programs. Despite significant investment, the gap between what is possible and what is achieved remains. Even after information, tools, and interventions have been successfully evaluated in their intended populations, the development of knowledge to support their broader dissemination and implementation has often remained outside the scope. The FY24 TBIPHRP HSRA intends to bridge the gap between research, practice, and policy by building real-world evidence on how interventions, clinical practices/guidelines, and policies can be deployed to targeted populations at the appropriate time.Research Scope: The FY24 HSRA will fund clinical research (including clinical trials). Preclinical and animal research are prohibited. Prospective or retrospective clinical research or clinical trials involving human subjects, human subject data/records, and human anatomical substances are allowed. Proposed clinical trials should include interventions, clinical practices/guidelines, and policies that are well-supported within the literature and in relevant patient population(s). This award may not be used to support studies requiring an exception from informed consent (EFIC).Key aspects of the FY24 TBIPHRP HSRA: Precision Medicine Approaches: When appropriate, the TBIPHRP encourages the use of precision medicine approaches. These tailored treatments deliver the right treatment at the right time while considering an individuals unique characteristics. Community-Based Participatory Research: The application must include Community-Based Participatory Research (CBPR) approaches in the development and execution of the clinical research/trial. CBPR approaches should be documented in Attachment 8. Preliminary data are required: Inclusion of preliminary data relevant to the proposed clinical research/trial is required. Untested novel interventions are discouraged: Novel interventions that have not been evaluated in the intended population(s) are discouraged. Applicants seeking funding for novel interventions should consider one of the other FY24 TBIPHRP announcements. Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Inquiry Review Board [IRB] review) are exempt from this requirement. Clinical Trial Start Date: If applicable, the proposed clinical trial is expected to begin no later than 6 months after the award date. Intervention Availability: If applicable, the application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study.The FY24 HSRA applications may include (not all inclusive): Research that accelerates the uptake and implementation of evidence-based research into clinical practice. Comparative effectiveness research comparing the benefits and harms of emerging or established interventions and strategies to prevent, diagnose, treat, and monitor health conditions in real-world settings. Development and evaluation of strategies to overcome barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines. Analysis of existing data or resources to inform clinical practice. Modification of established clinical tools for their intended population or environment. Analysis of existing clinical tools to maximize patient-relevant outcomes. Identification and analysis of the circumstances that create a need to stop or reduce (de-implement) the use of interventions, tools, policies, and guidelines that are ineffective, unproven, low-value, or harmful are within scope. Analysis of TBI and/or psychological health outcomes associated with the implementation of clinical practice guidelines, evidence-based practices, and process improvements.Early-Career Investigator Partnering Option: The FY24 TBIPHRP HSRA includes an Early-Career Investigator Partnering Option that is structured to accommodate two Principal Investigators (PIs), one of whom is an Early-Career Investigator. The combined direct costs budgeted for the entire period of performance in the applications of the Initiating PI and Partnering PI should not exceed $2.5M. The PIs may have experience in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. One PI will be identified as the Initiating PI and will be responsible for most of the administrative tasks associated with application submission. The other investigator will be the Partnering PI. At least one of the Initiating or Partnering PIs must be an Early-Career Investigator. The intent is not to create mentor-mentee arrangement. Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. The application is expected to describe how the PIs unique experience/expertise combined as a partnership will better address the research question, how the unique experience/expertise that each individual brings to the application is critical for the research strategy and completion of the SOW, and why the work should be done together rather than through separate efforts. If recommended for funding, each PI will be named to an individual award within the recipient organization(s). For individual FY24 TBIPHRP HSRA submission requirements for the Initiating and Partnering PI, refer to S Section II.D.2, Content and Form of the Application Submission.A clinical trial is defined in 45 CFR 46.102 as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/Human%20Subjects%20Resource%20Document.pdf.Clinical trials may be designed to evaluate pharmacologic agents (drugs or biologics), diagnostics, devices, therapies, clinical guidance, behavioral interventions, emerging approaches and technologies, and/or new indications for products currently U.S. Food and Drug Administration (FDA)-approved or -cleared. Interventions that are not FDA-regulated (or international equivalent) are within scope but the regulatory status must be documented in Attachment 12, Regulatory Strategy.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.Multi-Institutional Clinical Research/Trials: As of January 20, 2020, U.S. institutions engaged in non-exempt cooperative research must rely on a single IRB to review and approve the portion of the research conducted at domestic sites (45 CFR 46.114(b)). If the proposed, non-exempt research involves more than one U.S.-based institution, a written plan for single IRB review arrangements must be provided at the time of application submission or award negotiation. The lead institution responsible for developing the master protocol and master consent form should be identified and should be the single point of contact for regulatory submissions and requirements.Communication and data transfer between or among the collaborating institutions, as well as how specimens and/or imaging products obtained during the study will be handled, should be included in the appropriate sections of the application. A separate intellectual and material property plan agreed on by all participating institutions is also required for multi-institutional clinical research/trials.Relevance to Military Health: Relevance to the health care needs of Service Members, their Families, and Veterans is a key feature of this award. Investigators are encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health: Explanation of how the project addresses an aspect of psychological health conditions and/or TBI that has direct relevance to the health and/or readiness of Service Members, their Families, and Veterans. Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to benefit the civilian population and also address a military need. Use of military or Veteran populations, samples, or datasets in the proposed research, if appropriate.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $15.5M to fund approximately four HSRA applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This grant provides funding for researchers and organizations to analyze data from Mars missions, supporting advancements in our understanding of the planet's geology, climate, and potential for life.

With this solicitation, NIJ seeks to fund proposals for rigorous research and evaluation projects examining the impact of court and other criminal justice tools, practices, and policies on the administration of justice and public safety in state, local, and tribal jurisdictions. In FY2024, the solicitation is focused on four research priorities and their impact on charging, case flow, outcomes, and other prosecution functions: 1) advance prosecution practice and resource management; 2) promote fair prosecution and impartial administration of justice; 3) build prosecution data resources, research capacity, and transparency; and 4) enhance the prosecution workforce and court workgroup.

This grant provides financial support to San José-based nonprofit arts and cultural organizations that promote community engagement and contribute to the city's cultural vitality through diverse artistic programming.

This program provides funding and support to small businesses in Pennsylvania that are historically disadvantaged, helping them access capital and improve their participation in public contracts.

This funding opportunity provides financial support for organizations to create public engagement activities in Bangladesh that celebrate American values and culture in connection with the 250th anniversary of U.S. independence.

The Harland Jones Charitable Fund (HJCF), administered by the Community Foundation of Northeast Alabama (CFNEA), provides grants to 501(c)(3) qualified public charities in CFNEA's nine-county region. This grant program is aligned with the foundation's mission to support youth development through specific programming. Grant awards range from $1,000 to $10,000, with a one-year grant duration. Organizations must be tax-exempt, have at least one year of operating history after 501(c)(3) classification, and possess a board-approved strategic plan covering at least 24 months, including mission statement, strategic goals, and measurable objectives. The HJCF targets youth up to age nineteen, with a focus on programs that promote education, literacy, safety, and moral and physical development. The expected outcome is to provide charitable support to organizations that positively impact the lives of young people within the designated region. Measurable results would stem from the objectives outlined in the applying organizations' strategic plans, which are a required component of eligibility. The grant program's priorities clearly revolve around enhancing the well-being and development of youth. The foundation's strategic priorities, as reflected in the HJCF, emphasize direct support for operational charities rather than endowments, capital campaigns, or individual grants. This indicates a theory of change that focuses on empowering existing organizations with a proven track record to deliver services. The eligibility criteria regarding financial statements (audited, review, or compilation based on budget size) further suggest a commitment to responsible stewardship and accountability, ensuring that funds are directed to organizations capable of managing them effectively. Funding restrictions highlight areas that the foundation will not support, such as discriminatory practices, lobbying, political purposes, and organizations with less than one year of operation, or those with open grants in the same fund. This demonstrates the foundation's commitment to ethical practices, long-term impact, and ensuring equitable distribution of resources. The comprehensive guidelines ensure that grant funds are utilized for their intended charitable purposes, aligning with the overall strategic objective of fostering community development through targeted support for youth-focused programs.

The FY24 PCRP Idea Development Award is intended to support new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission. The key components of this award mechanism are: Innovation: Research deemed innovative may represent a new paradigm, challenge current paradigms, look at existing problems from new perspectives, leverage unique study populations, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative. Projects involving multidisciplinary and/or data science approaches are especially encouraged. Impact: Applications are required to address and provide a solution to one or more of the FY24 PCRP Overarching Challenges. The potential impact of the research, both short-term and long-term, in addressing the FY24 PCRP Overarching Challenge(s) should be clearly described. High-impact research will, if successful, significantly advance prostate cancer research and/or patient care. Preliminary Data: Due to this awards emphasis on innovation, the presentation of preliminary data relevant to prostate cancer and the proposed project is encouraged, but not required. Any unpublished, preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or a member(s) of the research team. Regardless of whether preliminary data are included, applications should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature.New Investigator category: The FY24 PCRP Idea Development Award mechanism encourages research ideas from investigators in the early stages of their careers. The New Investigator category of this award mechanism is designed to allow applicant organizations to name PIs who are early in their faculty appointments or in the process of developing independent research careers. Applications submitted to the New Investigator category will be assessed using different review criteria for personnel (refer to Section II.E.1.a., Peer Review) and are required to include a collaborator (or collaborators) who has (have) experience in prostate cancer research, as demonstrated by a record of funding and publications. The application must describe the potential of the collaboration(s) to be successful and how the collaboration(s) will augment the PIs expertise to better address the research question. In addition, applicants are strongly encouraged to provide a letter of collaboration from the collaborator(s) describing the collaborator(s) involvement in the proposed work. All applicants for the New Investigator category must meet specific eligibility criteria described in Section II.C, Eligibility Information.Multidisciplinary projects are encouraged, and multi-institutional projects are allowed. Each proposed study must include a clearly stated plan for interactions among all team members and organizations involved. The plan must include communication, coordination of research progress and results, and data transfer. Additionally, multi-institutional applications must provide an intellectual property plan to resolve potential intellectual and material property issues and to remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of this award.Investigators are strongly encouraged to incorporate the following components into their study design, where appropriate, in order to maximize the potential impact of the proposed research project: authentication of proposed cell lines; statistical rigor of preclinical animal experiments; and incorporation of experiments to assess clinical relevance and translatability of findings. Studies utilizing data that are derived from large patient studies that include long-term health records, biospecimen repositories, and pre-existing research and apply state-of-the-art genomic and/or proteomic analysis, bioinformatics, and/or mathematical models to such data are also encouraged. Investigators are highly encouraged to provide a letter of support indicating access to and the availability of any resources required to support the study.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 https://www.nature.com/nature/ journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP Idea Development Award should not exceed $1.2M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $53.76M to fund approximately 28 Idea Development Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The Greater Milwaukee Foundation offers grants to 501(c) (3) nonprofit organizations in the greater West Bend area, Wisconsin, prioritizing projects in arts and culture, education, family, youth, elderly, health and human services, community development, and historic preservation, with an application deadline of 10/07/2024.

This grant provides financial support to nonprofit organizations, schools, and libraries in the Black Hills region to address critical community issues such as education, mental health, substance abuse, and food security.

This funding opportunity supports innovative basic research in behavioral and social sciences to improve the Army's ability to develop and retain professional Soldiers, targeting universities, nonprofits, and commercial organizations.

This funding opportunity is designed to assist developers of direct air capture technologies in securing investment and operational support to scale up their projects and contribute to reducing carbon emissions.

This funding opportunity provides financial support to qualified nonprofits in the Metro Denver area to enhance their capacity and effectiveness through technical assistance activities.

The Office of Justice Programs (OJP) operates with a foundational mission deeply rooted in promoting civil rights and racial equity while fostering a strengthened justice system. The purpose of this specific solicitation is not for new projects but rather to invite organizations to apply for continuation funding to sustain specific, ongoing initiatives championed by the Bureau of Justice Assistance (BJA). This grant mechanism is designed to reinforce previously successful, funded projects, ensuring continuity and stability in efforts aligned with the OJP's core values. The OJP’s strategic priorities clearly define the target beneficiaries and core focus areas. The work is explicitly designed to increase access to justice, support crime victims, and assist individuals impacted by the justice system. Furthermore, significant attention is given to strengthening community safety and protecting the public from both existing and evolving threats. The overarching priorities that guide these initiatives include the advancement of civil rights, the realization of racial equity, and the critical objective of building trust and positive relationships between law enforcement agencies and the communities they serve. Consistent with the principles of effective investment, the solicitation itself represents a strategic priority of maintaining successful, data-driven interventions. The continuation funding model implies a Theory of Change centered on sustained impact, where initial investments that have demonstrated progress are prioritized for ongoing support to achieve long-term systemic change. This approach minimizes administrative churn and focuses resources on maturing initiatives that directly address the core mission. The exclusive nature of the application, limited only to those who received a direct letter from BJA, underscores this commitment to continuity and existing partnership performance. The expected outcomes and measurable results are inherently tied to the continuation of the original project’s goals, with the anticipation of sustained or improved performance in the targeted areas. By supporting the original project guidelines and funding rules, the OJP seeks tangible results such as demonstrably improved access to justice services, quantifiable increases in community-police trust, and measurable progress in advancing civil rights and racial equity within the justice sphere. Ultimately, the outcome is the continued progression toward a safer and more equitable society, driven by BJA initiatives that have already proven their value.

This grant provides funding for collaborative research teams of independent investigators to advance innovative solutions in melanoma prevention, treatment, and survivorship, with a focus on improving patient outcomes.